Roche, Chugai Weigh In As Tocilizumab Biosimilars Fail To Hit The Mark In Q3

While Roche admits that an acceleration of biosimilar competition to its blockbuster IL-6 inhibitor Actemra/RoActemra is anticipated in the final three months of the year, the Swiss originator has been surprised by the lack of challenge to its franchise so far.